Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Aldrich Syndrome

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Aldrich Syndrome in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Miki, H1
Nonoyama, S1
Zhu, Q1
Aruffo, A1
Ochs, HD1
Takenawa, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00004341]0 participants Observational1995-07-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Aldrich Syndrome

ArticleYear
Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1997, Volume: 8, Issue:2

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acid Sequence; Animals; Antibodies; Benzoquinon

1997